Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lux Biosciences’s PIP for uveitis drug wins European positive opinion
The pediatric investigation plan (PIP) covers children and young adults between the ages of two and 17 years who are affected with uveitis. An accepted PIP is a
The pediatric investigation plan (PIP) covers children and young adults between the ages of two and 17 years who are affected with uveitis. An accepted PIP is a
Under the terms of the agreement, Helsinn Healthcare will receive a worldwide exclusive license to ZP1846 and will be responsible for all further development, regulatory approvals, manufacturing, marketing
The agreement covers additional research to be conducted by Compugen and provides Merck Serono with an option to exclusively license the novel peptide for worldwide development and commercialization.
The trial did not demonstrate an appreciable difference between patients treated with CERE-120 versus those in the control group. Both groups showed an approximate seven point improvement in
This patent claims extended-release formulations containing the muscle relaxant cyclobenzaprine, including Amrix and expires February 26, 2025. The lawsuit is based upon abbreviated new drug applications (ANDA) filed
Study ART621/223 is a factorial-design, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy, immunogenicity and pharmacokinetics of different dose regimens of ART621 following multiple dose administration in
Bupropion Hydrochloride extended-release tablets, available in 150 and 300mg strength, are the generic equivalent of Wellbutrin XL for the treatment of major depressive disorder. Doug Boothe, CEO of
Verticor designs, develops, manufactures and markets spinal implants for fusion and motion preservation. Todd Stanaford, president of Verticor, said: “The name change was based on the company evolving
Under the terms of the agreement, HTG and Harvard Catalyst Laboratory for Innovative Translational Technologies (HC-LITT) will collaborate to generate a novel microRNA biogenesis assay that can measure
The addition of Targeted Molecular Diagnostics (TMD) to Quintiles’s global central laboratories is said to strengthen Quintiles’s service offerings in oncology. It is also expected to provide strong